Firstly, HR-positive patients accounted for a large proportion 91.7% (55/60) in our study; secondly, patients who had previously chosen four courses of DC or TC scheme had clinical characteristics with good prognoses, such as early TNM staging, low Ki67 expression, etc. In this regard, for early-stage breast cancer, the past subtype identification and therapeutic options of breast cancer have brought better benefits to these patients. This evidence concerns the gene MKI67 and breast carcinoma.